Tenderwize
Retour à la recherche

Distigmin Non-Exclusive Rebate Agreement

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Oct 31, 2026 · 64 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Distigmin (ATC-Code nach WHO: N07AA03)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

15 / 100

Facteurs de risque

Quantities are unknown and dependent on prescription behavior and patient numbers. No minimum volumes guaranteed.

The buyer may terminate the open-house procedure if exclusive agreements are concluded, typically 8-12 months after pub...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Supply of pharmaceutical products containing the active substance Distigmin (ATC N07AA03).
  • Non-exclusive rebate agreement under §130a Abs. 8 SGB V.
Afficher le résumé complet

This is an open-house model (non-competitive) for non-exclusive pharmaceutical rebate agreements under §130a Abs.8 SGB V for the active substance Distigmin (ATC N07AA03). The buyer is AOK PLUS, covering Saxony and Thuringia. No estimated value is provided; quantities are unknown and no minimum volumes are guaranteed. The agreement runs until 31 October 2026. Participation is open to any pharmaceutical manufacturer meeting the conditions, with rolling submission deadlines. This is not a typical public procurement but a voluntary transparency notice.

Risques

Quantities are unknown and dependent on prescription behavior and patient numbers. No minimum volumes guaranteed.

The buyer may terminate the open-house procedure if exclusive agreements are concluded, typically 8-12 months after pub...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Pharmaceutical manufacturer as defined in §4 Abs.18 AMG.
  • Company must have its seat in Germany, EU, or EEA (§9 Abs.2 AMG).
  • No minimum volume or exclusivity; quantities are demand-driven.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; participation is open to all eligible manufacturers.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Distigmin Non-Exclusive Rebate Agreement

Non-exclusive rebate agreement for pharmaceutical products containing Distigmin (ATC N07AA03). No guaranteed quantities. Contract ends 31 October 2026.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Oct 2024 - Oct 2026

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; participation is open to all eligible manufacturers.

Date limite

Deadline Oct 31, 2026

Détails de la procédure

Date de publication
15 Aug 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
492346-2024

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30